CA2344690C - Fructosamine-oxydase: antagonistes et inhibiteurs - Google Patents

Fructosamine-oxydase: antagonistes et inhibiteurs Download PDF

Info

Publication number
CA2344690C
CA2344690C CA2344690A CA2344690A CA2344690C CA 2344690 C CA2344690 C CA 2344690C CA 2344690 A CA2344690 A CA 2344690A CA 2344690 A CA2344690 A CA 2344690A CA 2344690 C CA2344690 C CA 2344690C
Authority
CA
Canada
Prior art keywords
triene
diabetes
human
patient
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2344690A
Other languages
English (en)
Other versions
CA2344690A1 (fr
Inventor
John Richard Baker
Garth James Smith Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Priority claimed from PCT/NZ1999/000161 external-priority patent/WO2000018392A1/fr
Publication of CA2344690A1 publication Critical patent/CA2344690A1/fr
Application granted granted Critical
Publication of CA2344690C publication Critical patent/CA2344690C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention se rapporte à des procédés servant à réduire les conséquences des dommages macrovasculaires et microvasculaires chez un patient diabétique, en recourant à l'inhibition et/ou l'antagonisme de la fructosamine-oxydase chez ce patient. Cette inhibition et/ou cet antagonisme peuvent impliquer l'utilisation d'agents de chélation au cuivre, d'analogues substrats ou de composés hydrazine.
CA2344690A 1998-09-25 1999-09-24 Fructosamine-oxydase: antagonistes et inhibiteurs Expired - Fee Related CA2344690C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
NZ33208498 1998-09-25
NZ332084 1998-09-25
NZ332079 1998-09-28
NZ33207998 1998-09-28
NZ33447199 1999-03-03
NZ334471 1999-03-03
NZ337042 1999-08-03
NZ33704299 1999-08-03
PCT/NZ1999/000161 WO2000018392A1 (fr) 1998-09-25 1999-09-24 Fructosamine-oxydase: antagonistes et inhibiteurs

Publications (2)

Publication Number Publication Date
CA2344690A1 CA2344690A1 (fr) 2000-04-06
CA2344690C true CA2344690C (fr) 2011-03-22

Family

ID=27484372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2344690A Expired - Fee Related CA2344690C (fr) 1998-09-25 1999-09-24 Fructosamine-oxydase: antagonistes et inhibiteurs

Country Status (6)

Country Link
JP (1) JP2003521453A (fr)
AU (1) AU772026B2 (fr)
CA (1) CA2344690C (fr)
DK (1) DK1115389T3 (fr)
ES (1) ES2461195T3 (fr)
PT (1) PT1115389E (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076340B2 (en) 2015-09-24 2024-09-03 Innolife Co., Ltd. Use of trientine to deliver copper to ischemic tissue

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117769415A (zh) * 2021-06-30 2024-03-26 株式会社村田制作所 铜螯合剂、抗癌剂和威尔逊病的预防或治疗剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0321863A (ja) * 1989-06-19 1991-01-30 Shimadzu Corp トリエチレンテトラミン類分析法及びその装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076340B2 (en) 2015-09-24 2024-09-03 Innolife Co., Ltd. Use of trientine to deliver copper to ischemic tissue

Also Published As

Publication number Publication date
JP2003521453A (ja) 2003-07-15
DK1115389T3 (da) 2014-05-12
CA2344690A1 (fr) 2000-04-06
ES2461195T3 (es) 2014-05-19
AU772026B2 (en) 2004-04-08
PT1115389E (pt) 2014-05-09
AU5887199A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
EP1115389B1 (fr) Fructosamine-oxydase: antagonistes et inhibiteurs
Stadler et al. Effect of endogenous nitric oxide on mitochondrial respiration of rat hepatocytes in vitro and in vivo
Solem et al. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration
Gassó et al. Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis
CA2279428C (fr) Composes et procedes concernant l&#39;utilisation d&#39;agents therapeutiques dans la prevention de complications diabetiques
AU2004298393A1 (en) Copper antagonist compounds
US20150196500A1 (en) Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits
JP3546227B2 (ja) グルタミンを用いるグルタチオンレベルの増大法
CA2245836A1 (fr) Utilisation de composes deprenyliques pour maintenir ou permettre de retrouver les fonctions des cellules nerveuses, ou pour eviter la perte de ces fonctions
CA2344690C (fr) Fructosamine-oxydase: antagonistes et inhibiteurs
NZ539272A (en) Using an antagonist or an inhibitor of Fructosamine oxidase to reduce minimising the effects of macrovascular and microvascular damage in a diabetic patient
AU2004200539A1 (en) Fructosamine oxidase: Antagonists and inhibitors
CA2385551A1 (fr) Composes fixant des metaux et leurs utilisations
WO2000066101A2 (fr) Procede permettant d&#39;inhiber la formation d&#39;un produit de glycation
CA2361575A1 (fr) Formulations a base de l-arginine utilisees dans le traitement de maladies, et leurs procedes d&#39;utilisation
JP2002528419A (ja) 糖尿病性合併症に対する化合物およびその治療的使用
CA2455805C (fr) Composes et procedes concernant l&#39;utilisation d&#39;agents therapeutiques dans la prevention de complications diabetiques
EP1671630A2 (fr) Formulations basées sur l-arginine pour le traitment des maladies et méthodes utilisants les memes
Zahlten Hepatic porphyrias and heme metabolism
GB2245491A (en) Inhibition of metabolic oxalate formation
Makhija et al. NADH dependent aminopyrine N-demethylation and lipid peroxidation during Baygon intoxication in hepatic and extrahepatic guinea pig tissues
AU2016203655A1 (en) Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed